Status:
UNKNOWN
Evaluation of Usage Patterns and Outcomes in Patients Receiving Ceftolozane/Tazobactan (C/T) in Brazilian Hospitals
Lead Sponsor:
D'Or Institute for Research and Education
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Brief Summary
Ceftolozane/Tazobactan (C/T) is a recent option to manage multidrug resistant gram-negative infections in hospital patients. Despite several randomized controlled trials describing safety and efficacy...
Detailed Description
A multicenter, retrospective real-world study of hospitalized patients in a large private network of hospitals in Brazil (Rede D´Or São Luiz). Clinical data will be collected from Epimed Monitor Datab...
Eligibility Criteria
Inclusion
- aged \> 18 years
- received at least 2 days of C/T (with or without other antibiotics).
Exclusion
- 1\) Patients who were not hospitalized in the ICU.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05267483
Start Date
April 1 2022
End Date
March 30 2023
Last Update
April 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
D'Or Institute for Research and Education (IDOR)
Rio de Janeiro, Brazil, 22281-100